Sarcopenia: difference between revisions
Diff·revision 6 → 7·00:58, 23 Jan 2025
Difference between revision 6 and revision 7 of Sarcopenia. 3 lines changed; the page grew by 419 bytes.
| Revision 6 — 23:12, 10 Jan 2025 CRP_Cormac (talk) expand §Definition and assessment 2,319 bytes +29 | Revision 7 — 00:58, 23 Jan 2025 ArchiveBot (talk) bot: normalise citation format 2,738 bytes +419 | ||
|---|---|---|---|
| 23 | Grip strength is the most widely used screening measure because it is quick, cheap and correlates with strength elsewhere. Its cut-offs are population- and device-specific, as reference intervals generally are.{{r|cruzjentoft2019}} | 23 | Grip strength is the most widely used screening measure because it is quick, cheap and correlates with strength elsewhere. Its cut-offs are population- and device-specific, as reference intervals generally are.{{r|cruzjentoft2019}} |
| 24 | 24 | ||
| + | 25 | Sarcopenic obesity — low muscle with high fat mass — is a recognised phenotype and is harder to detect, since body weight does not signal it and the muscle deficit is concealed by adiposity.{{r|heymsfield2015}} | |
| + | 26 | ||
| 25 | == References == | 27 | == References == |
| 26 | {{reflist}} | 28 | {{reflist}} |
| 27 | <ref name="cruzjentoft2019">Cruz-Jentoft AJ, Bahat G, Bauer J, et al. "Sarcopenia: revised European consensus on definition and diagnosis." ''Age and Ageing'' 48(1):16–31 (2019). DOI:10.1093/ageing/afy169. PMID 30312372.</ref> | 29 | <ref name="cruzjentoft2019">Cruz-Jentoft AJ, Bahat G, Bauer J, et al. "Sarcopenia: revised European consensus on definition and diagnosis." ''Age and Ageing'' 48(1):16–31 (2019). DOI:10.1093/ageing/afy169. PMID 30312372.</ref> |
| + | 30 | <ref name="heymsfield2015">Heymsfield SB, Gonzalez MC, Shen W, Redman L, Thomas D. "Weight loss composition is one-fourth fat-free mass." ''Obesity Reviews'' 15(4):310–321 (2014). PMID 24447775.</ref> | |
| 28 | <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). PMID 33567185.</ref> | 31 | <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). PMID 33567185.</ref> |
| 29 | 32 |